LYVE1 and metabolic dysfunction-associated steatohepatitis: Interestingly, liver inflammation and fibrosis further affect the LSEC molecular phenotype, leading to downregulation of LYVE-1 in liver cancer and cirrhosis [73], and of FcγRIIb in non-alcoholic steatohepatitis [74].